This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Shruti Sharma, PhD, and a team from the MCG Center for Biotechnology and Genomic Medicine, hope to focus in on a new treatment pathway for diabetic retinopathy.

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique ...

In a presentation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language ...

The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD). e-therapeutics plc, shared business updates across a variety of areas.

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy. Clinicians’ attitudes toward geography atrophy (GA) and treatment have been changing in the short ...

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference. There is a great need for more ...

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into ...

A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology ...

The Eye Care Network team was on site to share key data and interview presenters at the annual meeting held in Chicago, Illinois. The annual American Academy of Ophthalmology meeting was held in ...

The meeting is set to take place from November 8 to 10, 2024 at the Sheraton Times Square Hotel in New York City. The OSN New York Retina meeting is set to take place over the weekend of November 8 to ...

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic ...